This afternoon we watched Moderna drop -1.3% to a price of $128.3 per share. The large-cap Biotechnology company is now trading -40.58% below its average target price of $215.93. Analysts have set target prices ranging from $82.0 to $430.0 per share for Moderna, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 6.5%, and a short ratio of 5.44. The company's insiders own 9.61% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 68.3% of Moderna's shares being owned by this investor type.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Baillie Gifford and Company | 12% | 46,466,171 | $5,961,609,881 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 7% | 27,526,280 | $3,531,621,808 |
| 2023-03-31 | Blackrock Inc. | 7% | 25,093,158 | $3,219,452,247 |
| 2023-03-31 | State Street Corporation | 4% | 14,076,355 | $1,805,996,389 |
| 2023-03-31 | Flagship Pioneering Inc. | 3% | 12,886,743 | $1,653,369,166 |
| 2023-03-31 | Coatue Management LLC | 2% | 6,546,104 | $839,865,163 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 6,244,957 | $801,228,002 |
| 2023-03-31 | Theleme Partners LLP | 2% | 6,112,434 | $784,225,300 |
| 2023-03-31 | Morgan Stanley | 1% | 4,950,573 | $635,158,531 |
| 2023-03-31 | Wellington Management Group, LLP | 1% | 4,292,235 | $550,693,763 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Moderna.
